Filing status
- Accounts due
- 30 September 2027
- Last accounts
- 31 December 2025
- Conf. stmt due
- 12 August 2027
- Last conf. stmt
- 29 July 2026
T-Cypher Bio Holdings Limited
- Incorporated
- 28 August 2020 (6 years)
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- Owen Hughes
- Owned by
- Accounts type
- Group
- Region
- South East
- Address
- Barton House Unit 12The QuadrantAbingdonOX14 3YS
Officers 4 active
Officer details are public data from the Companies House register.
British
Born June 1965 (61)
Director · Appointed 22 June 2026
British
Born January 1982 (44)
Hughes, Owen
Director · Appointed 1 November 2024
American
Born September 1974 (52)
British
Born May 1971 (55)
Officer history (7 former)
22 June 2026
22 June 2026
15 March 2026
9 February 2026
1 November 2024
Appointed Hughes, Owen as Director
9 February 2024
29 June 2023
Resigned Ferneau, Philip James as Director
29 June 2023
29 June 2023
Resigned Ogg, Graham Stuart, Professor as Director
4 January 2023
25 August 2021
25 August 2021
2 August 2021
21 December 2020
18 November 2020
Appointed Ferneau, Philip James as Director
18 November 2020
Appointed Ogg, Graham Stuart, Professor as Director
18 November 2020
28 August 2020
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 28 August 2020
Owns 25–50% of shares
Holds 25–50% of voting rights
Public Limited Company
Reg. no. 09093331
Group structure 19 shown
Ownership group derived from the Companies House PSC register
Acionna Therapeutics Ltd Owns 50–75% of shares
Animal Dynamics Limited Owns 50–75% of shares
Archangel Lightworks Ltd Owns 25–50% of shares
Ascension Earth Resources Ltd Owns 25–50% of shares
Caudal Energy Limited Owns 25–50% of shares
Caudal Morlais Limited Owns 75–100% of shares
Circadian Therapeutics Limited Owns 75–100% of shares
Cora Biosciences Limited Owns 25–50% of shares
Credo Therapies Ltd Owns 50–75% of shares
Densix Limited Owns 25–50% of shares
Dyna Therapeutics Limited Owns 50–75% of shares
Eligentis Limited Owns 25–50% of shares
Evox Therapeutics Limited Owns 25–50% of shares
Fluorok Limited Owns 25–50% of shares
T-Cypher Bio Holdings Limited This company Owns 25–50% of shares
T-Cypher Bio Limited Owns 75–100% of shares
Financials
Balance sheet as at 31 December 2025 · group accounts
- Cash
- £50
- Current Ratio
- 1247.9x
Trend
Shareholder Funds
Balance sheet detail
| 2025 | 2024 | |
|---|---|---|
| Current Assets | £28,408,783 | £28,414,191 |
| Debtors | £28,408,733 | £28,414,142 |
| Cash | £50 | £49 |
| Creditors (< 1 year) | £22,766 | £0 |
| Net Current Assets | £28,386,017 | £28,414,191 |
| Shareholder Funds | £29,798,772 | £29,774,364 |
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 12 August 2026 | Change of details for a person with significant control |
Some other companies at this address
Other companies in this industry
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →